Clinical Management and Therapeutic Advances in Pediatric Patients with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
While surgical boundaries remain highly restricted in deep-tissue infiltrative PN, the introduction of targeted MEK inhibitors marks a pivotal therapeutic paradigm shift and improving timely access to these therapies may help prevent further functional deterioration in selected pediatric patients.